Biotech IPOs Charge Ahead as Tech Deals Stall, WSJ Reports

Biotechnology companies are driving the IPO market forward while technology listings have stalled, the Wall Street Journal reports.

The divergence marks a sharp reversal of the dealmaking pattern that defined the post-2020 listing boom, when software and internet names dominated new-issue calendars. According to the WSJ's account, investors are now steering new-issue demand toward drug developers and away from tech.

Why are biotech floats moving while tech deals stall?

The WSJ frames the split as a supply-and-demand story. Biotech issuers are finding buyers for new shares. Tech issuers are not.

For biotech, the IPO window functions differently than it does for most sectors. Drug developers routinely come public before generating product revenue, pricing their floats on clinical-trial data and pipeline milestones rather than earnings. That structure lets them tap public markets in narrow windows when specialist healthcare investors are willing to underwrite risk.

Technology companies, by contrast, face a market that rewards profitability and proven cash generation. Late-stage private tech firms that grew accustomed to headline valuations in earlier funding rounds have hesitated to price offerings into a market that may not honor those numbers.

The result, as the WSJ describes it, is a two-speed IPO market: biotech charging ahead, tech sitting still.

What does the split signal for the deal calendar?

A biotech-led IPO market carries distinct risks for underwriters and investors alike.

• Biotech newcomers often trade on binary clinical outcomes rather than revenue trajectories, which amplifies post-listing volatility.
• A tech dearth leaves the largest fee pools — mega-cap software and consumer-internet offerings — parked on the sidelines.
• Sector concentration in the new-issue calendar can compress quickly if healthcare sentiment turns, leaving the broader market without an engine.

The WSJ's reporting does not claim the biotech surge is permanent. IPO markets led by a single sector have historically proven fragile: when the leading group's window closes, overall issuance tends to fall with it.

The open question for bankers and issuers is whether the current biotech momentum widens into a broader reopening — or remains a specialist rally inside a market that tech, the sector that once powered record listing volumes, has yet to rejoin.